Search This Blog

Saturday, May 30, 2026

Incyte Phase 3 shows tafasitamab plus lenalidomide with R-CHOP significantly improves PFS and EFS

 

Incyte Phase 3 frontMIND trial shows tafasitamab plus lenalidomide with R-CHOP significantly improves PFS and EFS in previously untreated high-risk DLBCL

  • Results will support planned global regulatory filings for the tafasitamab plus lenalidomide and R-CHOP regimen in high-risk DLBCL.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)